2008
The expanding genetic overlap between multiple sclerosis and type I diabetes
Booth D, Heard R, Stewart G, Goris A, Dobosi R, Dubois B, Lorentzen Å, Celius E, Harbo H, Spurkland A, Olsson T, Kockum I, Link J, Hillert J, Ban M, Baker A, Sawcer S, Compston A, Mihalova T, Strange R, Hawkins C, Ingram G, Robertson N, De Jager P, Hafler D, Barcellos L, Ivinson A, Pericak-Vance M, Oksenberg J, Hauser S, McCauley J, Sexton D, Haines J. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes & Immunity 2008, 10: 11-14. PMID: 18987646, PMCID: PMC2718424, DOI: 10.1038/gene.2008.83.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAllelesAmino Acid SubstitutionAntigens, Differentiation, T-LymphocyteAustraliaBelgiumCase-Control StudiesConfidence IntervalsDiabetes Mellitus, Type 1FamilyGenetic Predisposition to DiseaseHumansLectins, C-TypeLinkage DisequilibriumMiddle AgedMonosaccharide Transport ProteinsMultiple SclerosisNorwayOdds RatioPolymorphism, Single NucleotideProbabilitySwedenTryptophanUnited KingdomUnited StatesConceptsSingle nucleotide polymorphismsSusceptibility genesAutoimmune susceptibility genesMultiple sclerosis susceptibility genesClustering of autoimmune diseasesAssociated with type I diabetesTrio familiesCD226 geneEvidence of associationNucleotide polymorphismsCLEC16A geneGenetic overlapGenesMultiple sclerosis dataType I diabetesMultiple sclerosisAutoimmune diseasesFamilial clusteringRs12708716CLEC16ARs763361
1992
Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction
Krumholz H, Pasternak R, Weinstein M, Friesinger G, Ridker P, Tosteson A, Goldman L. Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction. New England Journal Of Medicine 1992, 327: 7-13. PMID: 1598117, DOI: 10.1056/nejm199207023270102.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombolytic therapyRisk of deathMyocardial infarctionElderly patientsPatients 75 yearsST-segment elevationOnset of symptomsUse of streptokinaseOne-way sensitivity analysesDecision analytic modelYears of lifeCost-effective treatmentRelative reductionHospital deathStreptokinase therapyOlder patientsClinical circumstancesThrombolytic agentsInfarctionPatientsCost effectivenessTherapyLack of consensusStreptokinase